A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma
Latest Information Update: 27 Feb 2024
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 21 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 21 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 13 Sep 2023 Planned End Date changed from 30 Apr 2023 to 31 Dec 2023.